成人起病Still病患者达到缓解后停用托珠单抗的研究
本研究回顾性纳入48例接受静脉托珠单抗治疗的成人起病Still病患者,38例(79.2%)在治疗6个月后达到缓解,其中12例在缓解期停用托珠单抗。停药后1年内6例(50.0%)复发,平均复发时间5.5个月;复发组停药时托珠单抗给药间隔为21(14-35)天,短于未复发组的35(28-53)天(P=0.08)。
要点
- 38例(79.2%)在托珠单抗治疗6个月后达到缓解,其中12例在缓解期停药。
- 停药后1年内6例(50.0%)复发,平均复发时间5.5个月。
- 停药时泼尼松剂量<7 mg/天者复发少于不满足者(P=0.001)。
核心结论
- 停用托珠单抗后1年复发率为50.0%。
- 停药时托珠单抗给药间隔较长且泼尼松剂量较低的患者更可能成功停用托珠单抗。
研究设计与样本
- 回顾性研究,纳入2012年4月至2022年7月按Yamaguchi标准诊断的成人起病Still病并接受托珠单抗治疗的连续患者。
- 共48例接受静脉托珠单抗治疗且信息充分的成人起病Still病患者纳入分析。
主要发现
- 38例(79.2%)在托珠单抗治疗6个月后达到缓解,其中12例在缓解期停用托珠单抗。
- 停药后1年内6例(50.0%)复发,平均复发时间5.5个月;另6例(50.0%)维持缓解。
- 复发组与未复发组停药时疾病活动度无差异:全身特征评分P=0.24,铁蛋白P=0.46。
- 托珠单抗使用时长无差异(P=0.32);复发组停药时给药间隔为21(14-35)天,短于未复发组的35(28-53)天(P=0.08)。
- 末次托珠单抗治疗时泼尼松剂量<7 mg/天者复发少于不满足者(P=0.001)。
关键数值与推荐
- 成人起病Still病诊断依据Yamaguchi标准。
- 停药时泼尼松剂量<7 mg/天者复发少于不满足者(P=0.001)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: Tocilizumab, an IL-6 inhibitor, has been proven effective in patients with adult-onset Still's disease (AOSD). This study aimed to clarify whether tocilizumab can be discontinued after achieving remission and to identify factors relevant to its successful discontinuation. METHODS: Consecutive patients with AOSD diagnosed according to Yamaguchi's criteria from April 2012 to July 2022, who were treated with tocilizumab, were retrospectively reviewed. RESULTS: Forty-eight patients with AOSD treated with intravenous tocilizumab, with sufficient information, were included. Thirty-eight patients (79.2%) achieved remission after 6 months of tocilizumab treatment, 12 of whom discontinued tocilizumab during remission. Within 1 year after tocilizumab discontinuation, six patients (50.0%) recurred at a mean of 5.5 months, while the other six (50.0%) remained in remission. Between the non-recurrence and recurrence groups, no difference was found in disease activity at tocilizumab discontinuation (systemic feature score, P = 0.24; ferritin, P = 0.46). While the duration of tocilizumab use was not different (P = 0.32), the interval of tocilizumab administration at tocilizumab discontinuation in the recurrence group was 21 (14-35) days, which tended to be shorter than 35 (28-53) days in the non-recurrence group (P = 0.08). Patients with prednisolone dose <7 mg/day at last tocilizumab treatment had fewer recurrences than those without (P = 0.001). After recurrence, tocilizumab was resumed in half of the patients, resulting in successful disease control. CONCLUSIONS: The recurrence rate after tocilizumab discontinuation was 50% in 1 year. Patients who remained in remission with a longer interval of tocilizumab administration and lower prednisolone dose were likely to succeed in the withdrawal of tocilizumab.
引用
- Tamai H, Kondo Y, Takeuchi T, et al. Tocilizumab discontinuation after remission achievement in patients with adult-onset Still's disease. Rheumatology (Oxford). 2025. PMID: 38507702. doi:10.1093/rheumatology/keae179
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。